Articles from NovaBay Pharmaceuticals, Inc.
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC (“PRN”) for $11.5 million (the “Asset Sale”). The Asset Sale, representing substantially all of the assets of the Company, was consummated pursuant to the Asset Purchase Agreement dated September 19, 2024, as amended, which NovaBay stockholders approved at the Special Meeting of Stockholders (“Special Meeting”) reconvened on January 16, 2025. The Special Meeting has been further adjourned by the Company until January 30, 2025 at 11:00 a.m. Pacific time to allow additional time for stockholders to vote only on the last remaining proposal, Proposal Two, to approve the Company’s liquidation and dissolution (the “Dissolution”) pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the “Plan of Dissolution”).
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · January 23, 2025
![](https://mms.businesswire.com/media/20241209147545/en/2325756/22/novabay_logo_resized.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders:
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · December 9, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 7, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company’s proxy proposals, specifically to authorize and approve the sale of its eyecare business (the “Asset Sale Proposal”) and approve the voluntary liquidation and dissolution of the Company (the “Dissolution Proposal”). Proposal One (the Asset Sale Proposal) and Proposal Two (the Dissolution Proposal) are further described in the Definitive Proxy Statement, filed on October 16, 2024 (the “Special Meeting Proxy Statement”), as supplemented including by the Additional Definitive Proxy Soliciting Materials filed on November 6, 2024 and November 12, 2024.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 15, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC (“PRN”) to increase the base purchase price for the Company’s eyecare business from $9.5 million to $11.5 million. The Company has entered into an amendment (the “Amendment”) to its previously announced Asset Purchase Agreement, dated September 19, 2024, with PRN (the “Original PRN APA” and, as amended, the “PRN APA”). The Company's transaction with PRN remains subject to certain closing conditions, including receiving stockholder approval.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 6, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the Company’s board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC (“Refresh”) for an affiliate of Refresh to acquire the Company’s Avenova® brand and related assets is a “Superior Proposal” to the Company’s asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC (“PRN”).
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · October 29, 2024
![](https://mms.businesswire.com/media/20240920714392/en/2248840/22/Novabay.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a definitive asset purchase agreement (the “Agreement”) with PRN Physician Recommended Nutriceuticals, LLC (“PRN”) to sell the assets of its Avenova® brand and business for $9.5 million in cash. The transaction has been approved by the Company’s board of directors and is anticipated to close in the fourth quarter of 2024, subject to the satisfaction of customary closing conditions, including approval from the stockholders of NovaBay.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · September 20, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2024 and provides a business update.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · August 13, 2024
![](https://mms.businesswire.com/media/20240801558807/en/2203442/22/NBY_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · August 1, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports record sales of Avenova®-branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over Prime Day 2022.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 30, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants, Series F-1 warrants, Series F-2 warrants and Series F-3 warrants for gross proceeds of approximately $3.87 million, prior to deducting underwriting discounts and commissions and offering expenses. The offering proceeds include partial exercise of the underwriter’s over-allotment option to purchase additional shares of common stock, Series F-1 warrants, Series F-2 warrants and Series F-3 warrants.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 29, 2024
![](https://mms.businesswire.com/media/20240725797972/en/2197570/22/NBY_logo.jpg)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”), today announced the pricing of its underwritten public offering of 3,200,380 shares of common stock (or pre-funded warrants in lieu thereof), 3,200,380 Series F-1 warrants to purchase up to 3,200,380 shares of common stock, 3,200,380 Series F-2 warrants to purchase up to 3,200,380 shares of common stock and 3,200,380 Series F-3 warrants to purchase up to 3,200,380 shares of common stock. The combined public offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying Series F-1 warrant, Series F-2 warrant and Series F-3 warrant is $1.10.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 26, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces 20% discounts on Avenova®-branded eyecare products and product bundles during Amazon Prime Day being held July 16-17, 2024.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 16, 2024
![](https://mms.businesswire.com/media/20240711674681/en/2183242/22/NBY_logo.jpg)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) announces preliminary net revenue for the second quarter of 2024 of $2.4 million and for the first half of 2024 of $5.0 million, primarily derived from the Company’s eyecare products. Net revenue from the Company’s eyecare products increased by 9% for both the second quarter and the first half of 2024 over the corresponding periods in 2023. NovaBay also expects 2024 net revenue from the Company’s eyecare products to be approximately $10 million.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 11, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia, Inc. (NASDAQEYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, have commenced activities under a previously announced co-promotion agreement.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 1, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · June 28, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announces that the NYSE American LLC (“NYSE American”) has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · June 7, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. the “Company”) (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company’s Definitive Proxy Statement filed on April 18, 2024 with the Securities and Exchange Commission (the “SEC”) were approved by stockholders at its 2024 Annual Meeting of Stockholders held on May 28, 2024. Among the proposals, stockholders approved a reverse stock split and authorized the Company’s Board of Directors to determine the specific split ratio and effective date.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 29, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduction of an expanded line of Avenova® product bundles specifically designed to provide easy, affordable and effective solutions for individualized relief from dry eye symptoms. The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of the multifactorial nature of dry eye disease and the recommendation that personalized treatment beyond artificial tears may be important for successful management.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 13, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 9, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company’s largest sales channel. Sales through Amazon for April 2024 increased by more than 20% compared with April 2023.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 7, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 3, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products. The new and enhanced programs build upon the Company’s past highly productive marketing programs through proprietary channels including social media and email to cost-efficiently enhance customer loyalty and reach new prospective customers.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · April 22, 2024
![](https://mms.businesswire.com/media/20240419003631/en/2104001/22/NBY_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by May 18, 2024 advising of actions it has taken or will take to regain compliance with the continued listing standards by October 18, 2025 in order to continue its listing on the NYSE American.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · April 19, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · April 17, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · March 26, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · March 25, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAdoctor® skincare business including all product inventory for approximately $1.0 million in cash. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · March 14, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com. A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022. In addition, of the more than 13,000 customer reviews across all online channels, Avenova Spray averaged a 4.5-star overall rating.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · January 30, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union. The new products will combine Sonoma’s existing eye product Ocudox®, which has already received a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be marketed through Sonoma’s established European distribution network. This agreement brings together NovaBay’s deep knowledge of eye care reflected in its Avenova brand with Sonoma’s expertise in distributing hypochlorous acid products overseas.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · January 9, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes. A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here. In September 2023 NovaBay commercially launched its prescription amniotic membrane product Avenova® Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · December 6, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 9, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 2, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the launch of two new promotional programs for ophthalmologists and optometrists who help their patients manage the symptoms of chronic dry eye with Avenova®-branded products. Through the new Avenova Loyalty Program and Avenova Affiliate Program, top Avenova eyecare professionals will have access to special promotions specifically designed to increase the awareness of the full suite of Avenova products.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · October 11, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Harborside Hotel in Jupiter, Fla.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · October 2, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel. This prescription product is the only optic allograft manufactured using BioStem Technologies, Inc.’s (OTC: BSEM) proprietary process and is intended for use as a protective covering during the repair of ocular surfaces.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · September 14, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · September 11, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2023 and provides a business update.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · August 10, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2023 after market close on Thursday, August 10, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · August 8, 2023
![](https://mms.businesswire.com/media/20230714384475/en/841167/5/nby_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that sales of Avenova®-branded products reached a new record during the Amazon Prime Day event held July 11-12, 2023, with sales increasing 22% over Prime Day 2022 and 43% over Prime Day 2021.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 14, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces special pricing on Avenova®-branded products to Amazon prime members during Prime Day 2023, being held July 11-12.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 10, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will be sponsoring dry eye educational programs and offering special promotions on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · June 28, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will showcase its Avenova®-branded eyecare products at the 126th Annual American Optometric Association (AOA) Congress & 55th Annual American Optometric Student Association (AOSA) Conference: Optometry's Meeting® being held June 21-24, 2023 at the Walter E. Washington Convention Center in Washington, D.C. The full line of Avenova dry eye products will be displayed at booth #821 in exhibition hall D&E.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · June 20, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Dr. Audrey Kunin will appear on QVC®’s Girls Night In with Courtney & Jane on Tuesday, June 13, 2023 at 10:00 p.m. Eastern time to showcase DERMAdoctor®’s system for dry, rough, bumpy skin. The two-piece Ultra Duo set of KP Duty Scrub and KP Duty Lotion, both in the 8-ounce size, will be available at QVC for a special price of $56.50.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · June 12, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, Chief Executive Officer, will present a company overview at the Emerging Growth Virtual Conference on Wednesday, May 31, 2023 at 1:10 p.m. Eastern time (10:10 a.m. Pacific time).
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 24, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2023 and provides a business update.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 11, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
PhaseOne Health announces it has provided PhaseOne Skin and Wound Cleanser (PhaseOne) as part of a $3 million donation of medical supplies to Ukraine in partnership with the nonprofit HelpingUkraine.us. Formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid, PhaseOne (0.025% hypochlorous acid solution) is a proprietary wound care product used for cleansing and irrigation as part of surgical procedures, as well as for treating certain wounds, burns, ulcers and other injuries. PhaseOne is distributed in the U.S. by PhaseOne Health.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 5, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2023 after market close on Thursday, May 11, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 4, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces that China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading Chinese importer and marketer of branded pharmaceuticals and medical devices, has placed a $1 million order for NovaBay’s NeutroPhase Skin and Wound Cleanser. NovaBay has fulfilled this order and expects to recognize this revenue in the second quarter of 2023.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · May 1, 2023
![](https://mms.businesswire.com/media/20230426006103/en/841167/5/nby_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announced today that it has entered into a securities purchase agreement with institutional accredited investors (“Purchasers”) in connection with a private placement to issue secured senior convertible debentures (the “Debentures”) and two series of new warrants exercisable for NovaBay common stock (the “Warrants”). The private placement is expected to close upon the satisfaction of closing conditions in the securities purchase agreement, which is expected to occur on or about May 1, 2023 or as soon as practicable thereafter. NovaBay intends to use the net proceeds received from the offering for working capital and general corporate purposes. In addition, NovaBay agreed to reduce the exercise price of existing warrants exercisable for an aggregate of 1,647,310 shares of common stock held by the investors in the financing to $1.50.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · April 27, 2023
![](https://mms.businesswire.com/media/20230421005008/en/1768777/22/C%2BJ_cream_8oz_Pic.jpg)
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer and board-certified dermatologist Audrey Kunin, MD will introduce the new DERMAdoctor Comfort + Joy Psoriasis Therapeutic Moisturizing Cream with 3% Salicylic Acid as an on-air guest on the QVC network. The new product for the treatment and relief of symptoms of psoriasis will be featured on Jane & Shawn’s Beauty Secrets tonight at 10 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · April 21, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2022 and provides a business update. Financial results for 2022 include DERMAdoctor®, which NovaBay acquired on November 5, 2021.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · March 30, 2023
![](https://mms.businesswire.com/media/20230314005317/en/1737837/22/Eyeganics_FB_Ad_2.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed channel. Organic Tears has no additives or artificial chemicals and is the only lubricant eye drop certified by the USDA as 100% organic and preservative-free.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · March 14, 2023
![](https://mms.businesswire.com/media/20230307005090/en/1730035/22/BryPhoto_Avenova_2023_0209_16.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright®, a nutrient-rich, antioxidant-dense extract of the superfruit maqui berry, and high quality, natural triglyceride omega-3 oils to comfort dry eyes and support overall eye health.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · March 7, 2023
![](https://mms.businesswire.com/media/20230206005067/en/841167/5/nby_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Product Officer Audrey Kunin, MD will be a live on-air guest on two QVC network shows on February 7, 2023. Dr. Kunin will be discussing DERMAdoctor®’s problem-solving Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on “It Takes Two With Mary & Sandra” at 2 p.m. Eastern time and on “Girl’s Night In With Courtney & Jane” at 9 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · February 6, 2023
![](https://mms.businesswire.com/media/20230131005342/en/841167/5/nby_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Justin Hall, CEO, will present a company overview at the virtual Sequire Biotechnology Conference on Thursday, February 2 at 2:30 p.m. Eastern time. To register for the event, visit the Sequire Biotechnology website.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · January 31, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key wound and burn care specialists in the United States. PhaseOne is formulated with NovaBay Pharmaceuticals’ (NYSE American: NBY) patented, stable hypochlorous acid.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · January 17, 2023
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Chief Product Officer Audrey Kunin, MD will return for her fourth appearance this year on the QVC network. Dr. Kunin will discuss DERMAdoctor’s moisturizing Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on “Give Gorgeous – Gifts With Purchase” hosted by two of QVC’s most popular hosts, Jennifer Coffey and Terri Conn, on Saturday, November 19 at 4 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 17, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2022 and provides a business update. Financial results for the first nine months of 2022 include DERMAdoctor, which NovaBay acquired on November 5, 2021.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 14, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (the “Company”) (NYSE American: NBY) announces that today, following approval from the Company’s stockholders obtained at the Company’s November 10, 2022 special stockholders’ meeting, the Company’s Board of Directors (the “Board”) has approved the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a 1-for-35 reverse stock split of all outstanding shares of common stock of the Company. The Company anticipates that the 1-for-35 reverse stock split will be effective as of 4:15 p.m. New York City Time on Tuesday, November 15, 2022 (the “Effective Date”), and the Company’s common stock will begin trading on a split-adjusted basis on Wednesday, November 16, 2022.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 14, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2022 after market close on Monday, November 14, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · November 9, 2022
![](https://mms.businesswire.com/media/20221026005007/en/1609747/4/PP_Niacinamide_2303_4x5_%28002%29.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the newest addition to the DERMAdoctor® Picture Porefect® collection: 15% Niacinamide Pore Minimizing Serum. This new, high-potency formulation minimizes the size of visible facial pores while delivering free-radical-neutralizing antioxidants and collagen-supporting agents to reduce blackheads, skin discoloration, rough skin, acne, and oily or combination skin.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · October 26, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present a company overview at the LD Micro Main Event XV on Wednesday, October 26 at 8:00 a.m. Pacific time (11:00 a.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · October 19, 2022
![](https://mms.businesswire.com/media/20221018005510/en/841167/5/nby_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces significant orders for DERMAdoctor® Kakadu® C 20% Vitamin C Serum with Ferulic Acid & Vitamin E.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · October 18, 2022
![](https://mms.businesswire.com/media/20221010005181/en/841167/5/nby_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that select Avenova brand products and all DERMAdoctor brand products will be featured with discounts to Amazon Prime members during the Amazon Prime Early Access Sale being held October 11-12, 2022.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · October 10, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on October 3, 2022 it received a notice from the NYSE American LLC that the Company’s common stock has been selling for a low price per share for a substantial period of time. As a result, pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the Company must effect a reverse stock split of its common stock or otherwise demonstrate sustained price improvement within a reasonable period of time, which the NYSE American has determined to be no later than April 3, 2023, in order to continue its listing on the NYSE American.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · October 7, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). The conference is being held at the Sofitel Hotel New York. A webcast of the presentation will be available on the Events page of the company website.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · September 23, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders:
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · September 22, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Virtual Life Sciences Investor Forum on Thursday, September 15, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific Time). Management will be holding investor one-on-one meetings on September 16 and September 19-20. Investors can register for the conference to view the presentation and request a meeting here.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · September 13, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that Chief Product Officer Audrey Kunin, MD will return to the QVC network for her third on-air appearance this year to discuss DERMAdoctor’s revolutionary Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm. This problem-solving eczema treatment will be featured on “Girls’ Night In with Courtney & Jane” on Tuesday, September 13 at 9 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · September 12, 2022
![](https://mms.businesswire.com/media/20220909005127/en/841167/5/nby_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a Securities Purchase Agreement with certain institutional investors in connection with a private placement of 3,250 shares of a newly created Series C Non-Voting Convertible Preferred Stock (the “Series C Preferred Stock”) at a price of $1,000 per share, Series A-1 warrants (the “Series A-1 Warrants”) exercisable to purchase up to an aggregate of 18,055,557 shares of Company common stock at an exercise price of $0.18 per share and Series A-2 warrants (the “Series A-2 Warrants” and, collectively with the Series A-1 Warrants, the “Warrants”) exercisable to purchase up to an aggregate of 18,055,557 shares of Company common stock at an exercise price of $0.18 per share. The Company expects to receive gross proceeds from the private placement of approximately $3.25 million. The private placement is expected to close in the fourth quarter of 2022 on or about the date of effectiveness of Stockholder Approval and the Reverse Stock Split (each as defined below) (the “Stockholder Approval Date”) and subject to satisfaction of customary closing conditions in the Securities Purchase Agreement. The exercise price for the Warrants and the number of shares of Company common stock underlying the Warrants will be adjusted to reflect the Reverse Stock Split.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · September 9, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and six months ended June 30, 2022 after market close on Thursday, August 11, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · August 4, 2022
![](https://mms.businesswire.com/media/20220728005419/en/841167/5/nby_logo.jpg)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the launch of a new marketing campaign targeting the large and growing number of women who wear eyelash extensions. This campaign represents the first step in a larger growth initiative to introduce the Avenova brand to an entirely new group of beauty-based consumers.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 28, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the availability of select DERMAdoctor products at two popular U.S. online retailers, Target.com and Urbanoutfitters.com.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 21, 2022
![](https://www.businesswire.com/images/bwlogo_extreme.png)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces record sales of Avenova-branded products during Amazon’s Prime Day event (July 12-13). Sales of Avenova-branded products during the two-day event increased 27% over Prime Days 2021 and 48% over Prime Days 2020, and reached a new one-day all-time high since the product became available on Amazon.com in June 2019.
By NovaBay Pharmaceuticals, Inc. · Via Business Wire · July 15, 2022